To prolong persistence, deleting cytokine-inducible SH2-containing protein (CIS) (a negative regulator of interleukin (IL)-15) was shown to achieve synergism with IL-15 signalling in CAR-NK cells, leading to doubled persistence and tumour eradication in lymphoma xenografts [58]. This evidence concerns the gene IL15 and lymphoma.